Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lunesta, Crestor, Sanctura Among New Products In UnitedHealth Registry

Executive Summary

Sepracor's insomnia agent Lunesta, AstraZeneca's statin Crestor and Indevus' overactive bladder therapy Sanctura are among the new products to be included in UnitedHealth's postmarketing surveillance drug registry

You may also be interested in...



Atrovent, Spiriva Safety To Be Tracked In Pharmacy Active Surveillance Pilot

An active drug surveillance system pilot, directed by the Critical Path Institute (C-Path), will track safety and efficacy information for the chronic obstructive pulmonary disorder therapies Atrovent and Spiriva

Atrovent, Spiriva Safety To Be Tracked In Pharmacy Active Surveillance Pilot

An active drug surveillance system pilot, directed by the Critical Path Institute (C-Path), will track safety and efficacy information for the chronic obstructive pulmonary disorder therapies Atrovent and Spiriva

UnitedHealth Rx Registry Will Test Four Highest Prescribed NMEs In 2004

UnitedHealth is testing its new postmarketing surveillance drug database on the four most frequently prescribed new molecular entities launched in 2004

Topics

UsernamePublicRestriction

Register

OM004634

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel